VolitionRx Q3 2026 net loss narrows 30% to $3.8 million; revenue more than doubles to $1.6 million

PUBT · 2d ago
VolitionRx Q3 2026 net loss narrows 30% to $3.8 million; revenue more than doubles to $1.6 million
  • VolitionRx’s third-quarter 2026 net loss narrowed 30% year over year to $3.8 million.
  • Revenue more than doubled to approximately $1.6 million on increased recognition of deferred revenue.
  • Cash and cash equivalents totaled approximately $2.4 million at September 30; the outstanding $7.5 million convertible note balance was prepaid during the quarter.
  • Capture-Seq licensing discussions are active with several major liquid biopsy and diagnostic companies targeting early cancer detection and residual disease testing.
  • A French reimbursement submission for Nu.Q Lung Cancer is expected this quarter.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611121610PR_NEWS_USPR_____LN96458) on November 12, 2026, and is solely responsible for the information contained therein.